Navigation Links
Encision Enters Into Sales Representation Agreement With Caldera Medical
Date:3/25/2009

BOULDER, Colo., March 25 /PRNewswire-FirstCall/ -- Encision Inc. ("Encision") (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, has entered into an agreement with Caldera Medical, Inc. ("Caldera") to represent Caldera's line of products. Caldera's products include the Desara(R) Sling System for treating stress urinary incontinence which is estimated to affect 15 million women in the U.S. Encision will use its sales employees to supplement Caldera's sales team in introducing Caldera's products to physicians and hospitals.

"We are pleased to expand our product offerings to a key group of our target customers. Caldera's products are consistent with our desire to offer 'best in class' products to the surgical market," said Jack Serino, President and CEO of Encision.

"Through Encision's experienced sales representatives, we will expand coverage throughout the U.S. market and strengthen our presence in the marketplace. This is especially important as we continue to broaden our product portfolio with innovative new technologies," said Bryon L. Merade, CEO of Caldera.

About Encision:

Encision designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery. For more information, visit Encision's web site at www.encision.com.

About Caldera:

Caldera is dedicated to bringing innovative medical devices to the marketplace. Caldera focuses exclusively on differentiated, high-impact products across the gynecology,
'/>"/>

SOURCE Encision Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
7. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Sangui Partnership Enters a New Phase:

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...stCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglob...dthatithassubmittedaMAAtotheEuropeanMedicinesAgenc...nttherapyindevelopment,forthetreatmentofType1Gauch...laglucerasealfathathasbeensubmitted,withprevious,s...onaglobalsupplyshortageofthecurrentlyapprovedandma...
(Date:11/24/2009)...e/--HealthRoboticstodayannounced,thatithasformedan...rs.ThisrecentlyformedToronto-basedcompanywillopera...ket,install,andsupport,HealthRobotics,i.v.Roomofth...ctofferingsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM)...eonan"asneeded,basis"toitsstrategicpartnershipswit...
(Date:11/24/2009)...all/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC...ealthCareConference.TheconferencewillbeheldDecembe...esentonTuesday,December1at11:00a.m.EasternTimeinHo...onwillbeavailableat www.celltherapeutics.com ,andi...JaffrayHealthCareConference,NewYorkPalaceHotel,Hol...
(Date:11/23/2009)...communication, computation and more powerful ways ...e quantum states as carriers of information is an ...ve shown, mathematically, how to gently tease out ...ping the information intact. Their work is reporte... and highlighted with a Viewpoint in Physics ( ...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ical Animal Data Demonstrates Selective Survival A...after HIV Infection, RICHMOND, Calif., Sept. 18 /...(Nasdaq: SGMO ) announced today the presentation ...e made permanently resistant to,HIV infection by t...eases,(ZFN(TM)) and preferentially survive and exp...
...rings The New Face of Research - the New ISI Web o...nstitutions Throughout the Country, PHILADELPHIA ...The Thomson Corporation (NYSE: TOC ; TSX: TOC) an... worldwide research and,business communities, anno...a la Ciencia y la Tecnologia (FECYT) has renewed i...
...H TRIANGLE PARK, N.C., Sept. 18 ,Siemens Medical S...d Xintek Inc.,announce today that they have signed... in Research Triangle Park, N.C. The mission of th... a new multi-pixel X-ray source,technology for a b...ogo: http://www.newscom.com/cgi-bin/prnh/20070904...
Other Biology Technology:Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes 2
(Date:11/23/2009)...r 23, 2009 - The time of day matters to forest tre...produced by a research team led by Professor Malco...ice-principal for research and colleagues in the d...eorge campus. , Capitalizing on their previous... research team examined how poplar trees use their...
(Date:11/23/2009)... only swine vaccine available for the H1N1 virus h...th the virus. The vaccination marks the first time...ith the pandemic flu., Iowa State University,s H... the vaccine this summer and has been shipping pre...nd Illinois for several weeks., The latest vacci...
(Date:11/23/2009)...wo new studies reveal in unprecedented detail how ...emble new proteins and guide them toward their des...ecular dynamics flexible fitting (MDFF) to examine...t molecular partners. , The first study, in Pr...ncerns the intimate signaling between the ribosome...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3COSHAR Foundation Promotes Importance of Timely Childhood Immunization at Black Family Reunion Celebration in Washington D C 56444 1COSHAR Foundation Promotes Importance of Timely Childhood Immunization at Black Family Reunion Celebration in Washington D C 56444 2BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 4954 1BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 4954 24 Balzan 2009 prize winners announced in Milan 56438 14 Balzan 2009 prize winners announced in Milan 56438 2
...rability during ePassports EAC Conform...ept. 9 After successful deployment,of their first...gain has,selected Entrust, Inc. (Nasdaq: ENTU ) t...ond-generation ePassport solution based on the Ext...ovenia becomes one of the first,countries in the w...
...so-called triglycerides in specialized fatty tissu...he delicate balance of the lipid metabolism gets o... leading to the dreaded fatty liver. This increase... metabolic syndrome known as "deadly quartet". Thi...d hypertension is regarded as the primary cause of...
... France,s presidency of the EU, Lille will play ho...e GMES (Global Monitoring for Environment and Secu...s relating to the environment, climate change, res...e services draw on data - mainly Earth observation...combined with socio-economic data, processed in su...
Other Biology News:Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 3Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 4Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 5Cortisol and fatty liver: Researchers find cause of severe metabolic disorders 2Major European program for the environment under the spotlight in Lille, France 2
Human Complement C1r from BIOPUR
...on Designer designs oligos for SYBR Green, TaqMan,...NASBA and FRET assays. Highly specific primers are...tomatically interpreting BLAST search results. Pri...condary structures identified by connecting to the...
...ists of the LVF-HL, LVF-CUVADPT, FHS-LVF, and the ... and low-pass Linear Variable Filters to create th...nter wavelength and adjustable bandpass. Each filt...and blocking band (99.8%). These filters -- with ...
Custom siRNA, HPLC purified, annealed from Ambion
Biology Products: